Number of persons in whom recurrent HAS1 GVs were detected
| Type . | Tumor . | Hematopoietic . | Germline . | Germline/hematopoietic . | NCBI-SNP . |
|---|---|---|---|---|---|
| MM and WM Patients (n = 17) | |||||
| Percentage of patients with the indicated type of HAS1 GVs (n/n) | 59 (10/17) | 65 (11/17) | 94 (16/17) | 41 (7/17) | 88 (15/17) |
| No. of patients in whom HAS1 GVs were recurrent | 2-3 | 2-5 | 2-14 | 2-4 | 4-15 |
| Controls (n = 23) | |||||
| Percentage of controls with recurrent HAS1 GVs | 0 | 0 | 4-39 | 0 | 39-83 |
| No. of controls in whom HAS1 GVs were recurrent | 0 | 0 | 1-6 | 0 | 2-14 |
| Type . | Tumor . | Hematopoietic . | Germline . | Germline/hematopoietic . | NCBI-SNP . |
|---|---|---|---|---|---|
| MM and WM Patients (n = 17) | |||||
| Percentage of patients with the indicated type of HAS1 GVs (n/n) | 59 (10/17) | 65 (11/17) | 94 (16/17) | 41 (7/17) | 88 (15/17) |
| No. of patients in whom HAS1 GVs were recurrent | 2-3 | 2-5 | 2-14 | 2-4 | 4-15 |
| Controls (n = 23) | |||||
| Percentage of controls with recurrent HAS1 GVs | 0 | 0 | 4-39 | 0 | 39-83 |
| No. of controls in whom HAS1 GVs were recurrent | 0 | 0 | 1-6 | 0 | 2-14 |
A patient or control was counted as having the indicated type of GV if at least one such GV was detected in the samples that were sequenced.